Blood marker linked to concerns about thinking in midlife
Among 854 adults aged 45, higher marker levels were linked to thinking concerns, but not significantly linked to measured cognitive decline or poorer brain structure.
Our read
Biomarkers- Studied:
- Cohort study of 854 adults aged 45
- What changed:
- Higher plasma pTau181 was associated with self-reported cognitive concerns at age 45
- The catch:
- All participants were from one New Zealand birth cohort assessed at age 45
- In the record:
- The 27th paper on pTau181/ with results in people; 90 on record in all.
- Why it’s aging research:
- It bears on staying healthy in midlife and later life.
Editor of record: Boris Djordjevic · AgingResearch.News
An observational cohort study examined 854 adults aged 45 from a New Zealand birth cohort; 49% were female. Researchers measured pTau181, a blood protein studied as an Alzheimer’s disease marker. They also assessed self-reported thinking concerns, brain structure using scans, and biological aging using chemical marks on DNA. They assessed cognitive decline using tests from childhood and age 45.
Higher pTau181 levels were associated with self-reported thinking concerns. The researchers found no significant associations with measured cognitive decline, poorer brain structure or biological aging. The authors suggested that Alzheimer’s-related changes may begin accumulating by age 45 and may accompany subtle cognitive changes below objectively measurable levels.
Why it matters
Blood markers may help screen for Alzheimer’s disease risk. Understanding what they indicate in middle age matters before using them in people without the disease.
Caveats
These observational associations cannot establish that Alzheimer’s-related changes caused the reported concerns. The findings concern members of one New Zealand birth cohort without Alzheimer’s disease, assessed at age 45.
The paper
University of Otago
GeroScience, May 8, 2026, Open access
Comments
Be the first to comment.